Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 55, Topic 5
In Progress

Recovery, De-escalation, and Transition of Care in Methemoglobinemia & Dyshemoglobinemias

Lesson Progress
0% Complete
Recovery and De-escalation in Methemoglobinemia

Recovery, De-escalation, and Transition of Care in Methemoglobinemia & Dyshemoglobinemias

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Develop a structured plan for weaning intensive therapies, converting to enteral regimens, preventing Post-ICU Syndrome, and ensuring safe discharge and handoff.

1. De-escalation of Intensive Therapies

Once Methemoglobin (MetHb) levels and hemodynamics stabilize, a stepwise taper of intensive therapies is crucial to minimize complications and expedite recovery. The goal is to remove supportive measures as the patient’s intrinsic physiological function returns.

A. Criteria for Weaning Ventilatory and Hemodynamic Support

Before initiating de-escalation, the patient must meet several stability criteria:

  • Sustained SpO₂ ≥ 92% on FiO₂ ≤ 0.4
  • Methemoglobin < 10% by co-oximetry
  • Arterial pH > 7.35 with a clear downward trend in serum lactate
  • Mean Arterial Pressure (MAP) ≥ 65 mm Hg without escalating vasopressor requirements for at least 4–6 hours

B. Stepwise Reduction of Antidotal and Supportive Medications

The tapering process should be systematic, with frequent reassessment of the patient’s clinical status.

Medication Tapering Flowchart A flowchart showing the stepwise de-escalation process for methemoglobinemia treatment, starting with Methylene Blue, followed by Oxygen, IV Fluids, and adjunctive Ascorbic Acid. De-escalation Pathway 1. Methylene Blue: Repeat only if needed 2. Oxygen: Wean by 1-2 L/min q2-4h 3. IV Fluids: Convert to maintenance rate 4. Ascorbic Acid: Transition to PO
Figure 1: Stepwise De-escalation. A structured approach to weaning therapies, starting with the primary antidote (methylene blue) and progressing through supportive care measures as the patient stabilizes.
Pearl IconA shield with an exclamation mark. Clinical Pearls
  • Methylene Blue Dosing: Early tapering and avoidance of excessive doses (>7 mg/kg cumulative) is critical. High concentrations can inhibit NADPH methemoglobin reductase, paradoxically increasing MetHb levels and causing oxidative hemolysis.
  • G6PD Deficiency: Methylene blue is contraindicated in patients with known or suspected G6PD deficiency as it can induce severe hemolysis. Management relies on supportive care (oxygen, fluids) and, in refractory cases, exchange transfusion.

2. Conversion to Enteral Medications

Transitioning adjunctive therapies from intravenous to enteral routes is a key step toward ICU liberation. This can only occur once gastrointestinal tract integrity and motility are assured.

A. Assessment of GI Function

Before converting, verify GI function by confirming bowel sounds, assessing stool output, and checking for low gastric residual volumes. Ensure any enteral access tubes are correctly placed and patent.

B. Oral Alternatives and Dosing

  • Ascorbic Acid: Transition from IV to oral doses of 300–1000 mg every 6 hours. Dose adjustments may be necessary in patients with renal impairment.
  • Riboflavin: While data are limited, doses of 10–25 mg orally every 12 hours have been used as an adjunct in congenital methemoglobinemia.
  • Administration: Avoid sorbitol-containing liquid formulations which can cause diarrhea. Flush feeding tubes with at least 30 mL of water before and after medication administration to ensure delivery and prevent clogging.

C. Monitoring Effectiveness

After converting to enteral therapy, continue monitoring with serial co-oximetry every 6–12 hours until MetHb levels are consistently below 5%. Clinical improvement, including resolution of cyanosis and normalization of lactate, is also a critical indicator of successful absorption.

Pearl IconA shield with an exclamation mark. Clinical Pearls
  • The acidic environment of the stomach enhances the absorption of vitamin C (ascorbic acid).
  • If MetHb levels fail to decrease or begin to rise after switching to enteral therapy, immediately re-assess GI function and consider resuming IV therapy. This may indicate malabsorption or an ongoing exposure to an oxidizing agent.

3. Post-ICU Syndrome (PICS) Prevention

Implementing the ABCDEF bundle is a proactive, evidence-based strategy to mitigate the long-term cognitive, psychological, and physical impairments that can follow critical illness.

A. Identifying High-Risk Patients

Patients with the following characteristics are at higher risk for developing PICS:

  • Age > 65 years
  • Mechanical ventilation > 7 days
  • History of deep or prolonged sedation
  • Documented episodes of ICU delirium

B. Applying the ABCDEF Bundle

This bundle of practices should be integrated into daily ICU care to improve long-term outcomes.

The ABCDEF Bundle for PICS Prevention
Bundle Component Key Actions and Tools
Assess, Prevent, Manage Pain Use validated scales (CPOT, Numeric Rating Scale) to guide analgesia.
Both Spontaneous Awakening & Breathing Trials Pair daily interruption of sedation with a spontaneous breathing trial.
Choice of Sedation & Delirium Monitoring Prefer light sedation with agents like propofol or dexmedetomidine. Screen for delirium daily with the CAM-ICU.
Delirium (see above) (Integrated with Choice of Sedation)
Early Mobility & Exercise Initiate passive or active range-of-motion exercises within 48 hours of achieving hemodynamic stability.
Family Engagement & Education Involve caregivers in daily rounds, goal-setting, and discharge planning.
Pearl IconA shield with an exclamation mark. Clinical Pearl

Early mobilization not only reduces ICU-acquired weakness but can also improve peripheral perfusion. This may enhance the accuracy of peripheral monitoring devices like pulse co-oximeters, providing a more reliable assessment of oxygenation status during recovery.

4. Medication Reconciliation and Discharge Planning

A meticulous review of all medications, combined with robust patient education and structured checklists, is essential to prevent recurrence of methemoglobinemia and avoid hospital readmission.

A. Comprehensive Medication Review

The most critical step is to identify and permanently discontinue the causative oxidizing agent. Review all home, inpatient, and over-the-counter medications.

Common Oxidizing Agents to Discontinue:

  • Dapsone
  • Topical Anesthetics (Benzocaine)
  • Nitrates / Nitrites
  • Sulfonamides
  • Phenazopyridine
  • Aniline dyes
  • Rasburicase
  • Primaquine

B. Patient and Caregiver Education

Empower the patient and their family with knowledge to manage their condition and prevent future episodes:

  • Provide a wallet card that clearly states the diagnosis of methemoglobinemia, lists contraindicated drugs, and includes emergency contact information.
  • Teach the key signs and symptoms of recurrence (cyanosis, shortness of breath, fatigue, headache) and instruct on when to seek immediate medical care.

C. Outpatient Follow-up and Monitoring

Ensure a safe transition by scheduling appropriate follow-up:

  • Schedule a follow-up appointment with co-oximetry testing 1–2 weeks post-discharge. The interval should be tailored based on the etiology (e.g., more frequent monitoring for ongoing exposure vs. a single accidental exposure).
  • For suspected congenital cases, arrange a formal consultation with hematology and/or genetics.

5. Interprofessional Handoff and Communication

Structured communication tools and early coordination across disciplines are vital to ensure continuity of care and anticipate potential for relapse.

A. Structured Handoff Tools

Utilize a standardized format like SBAR to ensure all critical information is conveyed during transitions of care (e.g., from ICU to medical floor, or at discharge).

SBAR Handoff Tool Diagram A diagram illustrating the four components of the SBAR communication tool: Situation, Background, Assessment, and Recommendation, used for effective clinical handoffs. S Situation Current MetHb, vitals, status B Background Etiology, cause, treatments given A Assessment Key labs, residual deficits, concerns R Recommendation Follow-up plan, med adjustments
Figure 2: The SBAR Framework. Using a structured handoff tool like SBAR ensures that critical information regarding the patient’s condition, treatment, and follow-up plan is clearly and concisely communicated between care teams.

B. Coordination with Care Teams

Proactively notify the patient’s primary care physician, consulting specialists (e.g., hematology), and outpatient pharmacy of the diagnosis, causative agent, and detailed follow-up plan. Engage case management or social work early to address any barriers to a safe discharge.

Pearl IconA shield with an exclamation mark. Clinical Pearl

Brief, daily interdisciplinary “huddles” during the patient’s ICU stay can significantly reduce miscommunication. These meetings allow the entire team to align on the daily goals of care, anticipate discharge needs, and identify potential gaps before the patient leaves the critical care environment.

6. Quality Metrics and Continuous Improvement

Tracking key outcomes and patient-reported data is essential for refining institutional protocols, improving patient safety, and enhancing the overall patient experience after an episode of methemoglobinemia.

A. Readmission and Recurrence Rates

A primary quality indicator is the 30-day readmission rate specifically for methemoglobinemia. A target of < 5% is an ambitious but achievable goal, reflecting successful patient education and medication reconciliation.

B. Patient-Reported Outcomes and Satisfaction

Beyond clinical data, it is important to measure the patient’s recovery from their perspective. This can be accomplished through:

  • Administering quality-of-life surveys (e.g., EQ-5D, SF-36) at 3 months post-discharge.
  • Tracking the incidence of PICS and monitoring institutional compliance with the ABCDEF bundle.

Editor’s Note: Institution-specific metrics for long-term neurologic and quality-of-life outcomes are encouraged but require dedicated local data collection infrastructure. Tracking these outcomes can provide deeper insights into the true burden of critical illness and the effectiveness of recovery programs.

References

  1. Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of congenital and acquired methemoglobinemia. Am J Hematol. 2021;96(12):1666–1678.
  2. Cefalu JN, Joshi TV, Rielly-Gauvin K, et al. Methemoglobinemia in the Operating Room and Intensive Care Unit: A Review of the Pathophysiology, Recognition, and Management. Adv Ther. 2020;37(5):1714–1723.
  3. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
  4. Evans L, Rhodes A, Alhazzani W, et al. Critical Care Transition Programs and Post-ICU Discharge Planning: A Scoping Review and an International Critical Care Societies’ Statement. Crit Care Med. 2021;49(11):e1116–e1120.
  5. Rino PB, Velez LI, Kleshinski JF, et al. A validated case of ascorbic acid for the treatment of methemoglobinemia. Am J Ther. 2014;21(4):240–243.
  6. Singh P, Lath S, Teli A, et al. Therapeutic whole blood exchange in severe methaemoglobinaemia: A case series. Transfus Med. 2020;30(3):231–239.